Trade Summary

5 days ago, Schneider Eugene, serving as EVP, Chf Clinical Develop Ofcr at IONIS PHARMACEUTICALS INC (IONS), sold 26,000 shares at $81.05 per share, for a total transaction value of $2,107,196.00. Following this transaction, Schneider Eugene now holds 77,114 shares of IONS.

This sale represents a 25.21% decrease in Schneider Eugene's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, June 26, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, June 30, 2026 at 5:48 PM ET, 4 days after the trade was made.

IONIS PHARMACEUTICALS INC operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.